Our leadership team

Joaquin Duato is Chairman and Chief Executive Officer of Johnson & Johnson. Under his leadership, J&J is now exclusively focused on tackling the toughest health challenges by developing innovative medicines and medtech solutions.

Vanessa Broadhurst is Executive Vice President, Global Corporate Affairs, and is a member of the Executive Committee. In this role, Vanessa is responsible for advancing our strategy across Corporate Marketing, Global Communications, Health Equity, and Philanthropic giving. She leads a world-class team who are passionate about changing the of health of humanity.

Liz Forminard is Executive Vice President, Chief Legal Officer for Johnson & Johnson and a member of the Company’s Executive Committee. She serves as legal advisor to the Board of Directors and company executives and is responsible for shaping legal strategy worldwide. Liz also oversees the Company’s Environmental, Social and Governance strategy, Office of the Corporate Secretary, and Privacy organization. In addition, she serves as the executive sponsor of the Open & Out LGBTQ+ Employee Resource Group.

Kristen Mulholland is Executive Vice President, Chief Human Resources Officer, responsible for global talent, recruiting, diversity and inclusion, compensation, benefits, employee relations and all aspects of the human resources agenda for Johnson & Johnson. Kristen is a member of the Executive Committee, Compensation Committee and HR Digital Council, and Chair of the Pension and Benefits.

As Executive Vice President, Innovative Medicine, R&D and Johnson & Johnson (J&J) Executive Committee member, John’s mission is to focus the best research and development teams in the world at the intersection of unmet medical need and innovation to change the trajectory of human health. A biomedical research leader with a distinguished career across nonprofit, academia, and industry, John encourages a culture that is fast-paced and open to reimagining how life-saving medicines are discovered, developed and delivered. Employing multiple drug modalities, John’s team works across a wide range of areas, including oncology, immunology, neuroscience, cardiovascular diseases, pulmonary hypertension, and retinal disorders.

As Executive Vice President and Worldwide Chairman of MedTech at Johnson & Johnson, Tim Schmid is transforming the future of healthcare. Under Tim‘s leadership, the $27B organization of 70,000+ employees is focused on developing and delivering medical technologies that help save lives, change the course of disease, and restore health.

Jim Swanson is Executive Vice President, Chief Information Officer, and member of the Executive Committee for Johnson & Johnson. Based at Johnson & Johnson’s USA headquarters, Jim is responsible for accelerating Johnson & Johnson’s business outcomes and advancing human health with technology and digital innovation.

Jennifer L. Taubert is Executive Vice President and Worldwide Chairman, Innovative Medicine at Johnson & Johnson, the world’s largest healthcare company. She is a member of the Corporation’s Executive Committee and leads the Innovative Medicine Group Operating Committee.

Kathryn E. Wengel (Kathy) is Executive Vice President, Chief Technical Operations & Risk Officer for Johnson & Johnson, and a member of the Company’s Executive Committee. She has significant healthcare, operations and global business expertise – with more than three decades of experience in leadership positions at Johnson & Johnson.

Joseph J. Wolk (Joe) is the Executive Vice President and Chief Financial Officer for Johnson & Johnson. Joe serves as a member of the company’s Executive Committee, playing a strategic role in the overall management of the organization and leading the development and execution of the business’ global long-term financial strategy. Additionally, as the financial steward of Johnson & Johnson, Joe’s scope of responsibilities includes driving competitive and profitable growth, generating sustainable cash flow, allocating capital to maximize value creation and managing risk across the entire enterprise.

Joaquin Duato is Chairman and Chief Executive Officer of Johnson & Johnson. Under his leadership, J&J is now exclusively focused on tackling the toughest health challenges by developing innovative medicines and medtech solutions.

Mr. Adamczyk, age 58, served as Executive Chairman of Honeywell International Inc. since June 2023 and was first elected as Chairman in April 2018. Mr. Adamczyk also served as Chief Executive Officer from March 2017 to June 2023. Mr. Adamczyk was President and Chief Executive Officer from March 2017 to April 2018 and Chief Operating Officer from April 2016 to March 2017. From April 2014 to April 2016, Mr. Adamczyk served as President and CEO of Honeywell Performance Materials and Technologies (PMT). Prior to serving as President and CEO of PMT, Mr. Adamczyk served as President of Honeywell Process Solutions from 2012 to 2014 and as President of Honeywell Scanning and Mobility from 2008 to 2012. Mr. Adamczyk joined Honeywell in 2008 when Honeywell acquired Metrologic, Inc., where he was the Chief Executive Officer. Prior to Metrologic, Mr. Adamczyk held several general management assignments at Ingersoll Rand, served as a senior associate at Booz Allen Hamilton, and started his career as an electrical engineer at General Electric. He is a member of the US-China Business Council, Business Roundtable and Business Council.

Dr. Beckerle, age 69, has served as Chief Executive Officer of the Huntsman Cancer Institute at the University of Utah since 2006. She is the Associate Vice President for Cancer Affairs and a Distinguished Professor of Biology and Oncological Sciences at the University of Utah. Dr. Beckerle joined the faculty of the University of Utah in 1986 and currently holds the Jon M. Huntsman Presidential Endowed Chair. Dr. Beckerle has served on the National Institute of Health (NIH) Advisory Committee to the Director, on the Board of Directors of the American Association for Cancer Research, on the Board of Scientific Advisors for the National Cancer Institute, as President of the American Society for Cell Biology and as the Chair of the American Cancer Society Council for Extramural Grants. She currently serves on a number of scientific advisory boards, including the Medical Advisory Board of the Howard Hughes Medical Institute and external advisory boards for comprehensive cancer centers at Duke, Georgetown, and University of Pennsylvania. Dr. Beckerle is also an elected Member of the National Academy of Science, the American Academy of Arts and Sciences, and the American Philosophical Society.

Dr. Doudna, age 60, joined the faculty at University of California, Berkeley, as a Professor of Biochemistry & Molecular Biology in 2002. She directs the Innovative Genomics Institute, a joint UC Berkeley-UC San Francisco center, holds the Li Ka Shing Chancellor’s Professorship in Biomedical and Health, and is the Chair of the Chancellor’s Advisory Committee on Biology at UC Berkeley. Dr. Doudna is Principal Investigator at the Doudna Lab at UC Berkeley and has founded and serves on the Scientific Advisory Boards of Caribou Biosciences, Inc. and Intellia Therapeutics, Inc., both leading CRISPR genome engineering companies. She has been an Investigator with the Howard Hughes Medical Institute since 1997. Dr. Doudna is the recipient of numerous scientific awards in biochemistry and genetics, including the Nobel Prize in Chemistry in 2020. Dr. Doudna is a Trustee for Pomona College.

Ms. Hewson, age 70, served as the Executive Chairman of Lockheed Martin Corporation (aerospace) from June 2020 until March 2021, as Chairman, President and Chief Executive Officer from January 2014 to June 2020 and held the positions of Chief Executive Officer and President from January to December 2013. Ms. Hewson served as a Director of Lockheed Martin Corporation from 2012 through March 2021. Ms. Hewson currently serves on the Boards of Chevron and Nexii Building Solutions. Ms. Hewson is a fellow of the American Institute of Aeronautics and Astronautics and a member of the American Academy of Arts and Sciences, Trilateral Commission, Council on Foreign Relations, Council of Chief Executives, and the University of Alabama President’s Cabinet and Culverhouse College of Business board of visitors.

Dr. Johnson, age 64, has served as the President of Wellesley College since 2016. She is a physician-researcher specializing in cardiology who founded and served as the inaugural Executive Director of the Connors Center for Women’s Health and Gender Biology at Brigham and Women’s Hospital from July 2002 to June 2016. Dr. Johnson served as the Chief of the Division of Women’s Health at Brigham and Women’s Hospital from July 2002 to June 2016. She was also a Professor of Medicine at the Harvard Medical School and Professor of Epidemiology at the Harvard School of Public Health. She is a member of the National Academy of Medicine and the American Academy of Arts and Sciences. She has been recognized with several honorary doctorates and other prestigious awards. She has served as a member of the Board of Trustees of the Rockefeller University since November 2021 and as a Director of the Isabella Stewart Gardner Museum since 2015.

Mr. Joly, age 64, served as the Executive Chairman of Best Buy Co., Inc. (consumer electronics) from June 2019 to June 2020, having joined the company in 2012 as President and Chief Executive Officer and becoming Chairman, President, and Chief Executive in 2015. From 2004 to 2008, he was Global President and Chief Executive Officer, Carlson Wagonlit Travel, and then served as President and Chief Executive Officer of Carlson Companies from 2008 to 2012. In 1999, he joined Vivendi as Global Chief Executive Officer, Vivendi Universal Games, and was later appointed Executive Vice President of U.S. Assets and Deputy Chief Financial Officer of Vivendi Universal. Prior roles included, from 1996 to 1999, Vice President, Europe and President of Electronic Data Systems France and, from 1983 to 1996, McKinsey & Company, eventually serving as Partner. Mr. Joly is a Senior Lecturer of Business Administration at Harvard Business School and serves on the Board of Directors of Sciences Po Foundation, the Board of Trustees of the Minneapolis Institute of Art, the New York Public Library and the International Advisory Board of his alma mater, HEC Paris.

Dr. McClellan, age 60, became the inaugural Director of the Duke-Margolis Institute for Health Policy and the Margolis Professor of Business, Medicine and Policy at Duke University in January 2016. He is also a faculty member at Dell Medical School at The University of Texas in Austin. Previously, he served from 2007 to 2015 as a Senior Fellow in Economic Studies and as Director of the Initiatives on Value and Innovation in Health Care at the Brookings Institution. Dr. McClellan served as Administrator of the Centers for Medicare & Medicaid Services for the U.S. Department of Health and Human Services from 2004 to 2006 and as Commissioner of the U.S. Food and Drug Administration (FDA) from 2002 to 2004. He served as a Member of the President’s Council of Economic Advisers and as Senior Director for Healthcare Policy at the White House from 2001 to 2002 and, during the Clinton administration, held the position of Deputy Assistant Secretary for Economic Policy for the Department of the Treasury. Dr. McClellan previously served as an Associate Professor of Economics and Medicine with tenure at Stanford University, where he also directed the Program on Health Outcomes Research. Dr. McClellan is the founding Chair and Senior Advisor to the Board of the Reagan-Udall Foundation, is a Member of the National Academy of Medicine and the Academy’s Leadership Consortium for Value and Science-Driven Health Care, and Co-Chairs the Guiding Committee of the Health Care Payment Learning and Action Network. He sits on the Boards of Directors of ResearchAmerica!, National Alliance for Hispanic Health, and United States of Care, as well as PrognomIQ Inc.

Ms. Mulcahy, age 71, was Chairman and Chief Executive Officer of Xerox Corporation (business equipment and services) until July 2009, when she retired as CEO after eight years in the position. Prior to serving as CEO, Ms. Mulcahy was President and Chief Operating Officer of Xerox. She also served as President of Xerox’s General Markets Operations, which created and sold products for reseller, dealer and retail channels. Earlier in her career at Xerox, which began in 1976, Ms. Mulcahy served as Vice President for Human Resources with responsibility for compensation, benefits, human resource strategy, labor relations, management development and employee training; and as Vice President and Staff Officer for Customer Operations, covering South America and Central America, Europe, Asia and Africa. Ms. Mulcahy was the U.S. Board Chair of Save the Children from March 2010 to February 2017, and was appointed as a Trustee in February 2018.

Mr. Weinberger, age 62, served as the Global Chairman and Chief Executive Officer of EY (Ernst & Young) (professional services) from 2013 through June 2019, having served as Global Chairman and CEO-elect in the prior year. He was Assistant Secretary of the U.S. Treasury in the George W. Bush Administration and was appointed by President Bill Clinton to serve on the U.S. Social Security Administration Advisory Board. Mr. Weinberger serves as a Senior Advisor to Stone Canyon Industries Holdings Inc. and Teneo. He is an Executive Advisor to G100 and World 50. Mr. Weinberger also serves as a Strategic Advisor to the Board of FCLTGlobal, which focuses on long-term investing and corporate governance. Mr. Weinberger is on the CEO Advisory Council of JUST Capital. He sits on the Board of Directors of the National Bureau of Economic Research (NBER), is a Senior Advisor to Chief Executives for Corporate Purpose (CECP) and is a member of the Aspen Economic Strategy Group. He is a member of the Boards of Trustees for Emory University, Case Western Reserve University, The Concord Coalition, The Greater Washington Partnership and US Council for International Business.

Dr. Nadja West, age 62, retired from the U.S. Army with the rank of Lieutenant General in October 2019. She served as the 44th Army Surgeon General, and the Commanding General of the U.S. Army Medical Command from 2015 to 2019, overseeing the highest medical readiness and battlefield wound survival rates in history. As the Joint Staff Surgeon from 2013 to 2015, Dr. West was the principal medical advisor to the Chairman of the Joint Chiefs of Staff at the Pentagon, where she coordinated all related health services issues, including operational medicine, force health protection and readiness within the military. Her prior roles include Deputy Chief of Staff for Support, U.S. Army Medical Command from 2012 to 2013, ensuring proper resources and support for smooth operation of the entire command. From 2010 to 2012, Dr. West served as Commanding General of the Europe Regional Medical Command. She is the recipient of numerous U.S. military awards, including the Distinguished Service Medal, the Defense Superior Service Medal and the Legion of Merit with three Oak Leaf Clusters. Dr. West currently serves as Trustee of both the National Recreation Foundation and Mount St. Mary’s University; on the Board of Governers of the National Collegiate Athletic Association (NCAA); and board member of Americares, The Olmsted Scholar Foundation and The Woodruff Foundation.

Eugene A. Woods, MBA, MHA, FACHE, is Chief Executive Officer, Advocate Health, one of the largest non-profit health systems in the country – created from the combination of Advocate Aurora Health and Atrium Health. The organization has nearly 155,000 teammates, serving over six million patients in North Carolina, South Carolina, Georgia, Alabama, Wisconsin and Illinois. Advocate Health also offers among the nation’s largest graduate medical education programs, with over 2,000 residents and fellows.